Early Diagnosis and Therapeutic Intervention to Improve Outcomes for Patients With Alzheimer’s Disease

Early Diagnosis and Therapeutic Intervention to Improve Outcomes for Patients With Alzheimer’s Disease

Program Overview

This activity includes four 30-minute modules that bring learners up to date on all aspects of treatment and management of patients with Alzheimer’s disease (AD). Dr. Richard S. Isaacson interviews four experts in the field of AD, each with their own specialization. The individual modules will focus on different areas of AD care, including early diagnosis and disease monitoring, the role of beta amyloid and tau, non- pharmacological approaches, and managing patients. Each module is worth 0.5 CME/CNE credits.

Target Audience

Neurologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Educational Objectives

1. Discuss recent developments in the diagnosis of AD such as the role of beta-amyloid and tau biomarkers in pathology and disease progression

2. Analyze clinical trial data of emerging therapeutics to delay progression in the treatment of AD

3. Evaluate non-pharmacologic approaches for the treatment of AD

4. Review the pathology of Alzheimer’s disease, including disease monitoring and specific biomarkers for early diagnosis

5. Implement shared decision making with the interprofessional team to develop individualized treatment plans to improve the quality of life for patients with AD


I. The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging
II. Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression
III. Non-Pharmacological Approaches to Managing Patients With AD
IV. Early Diagnosis and Disease Monitoring: Pathology and Biomarkers


Richard S. Isaacson, MD
Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Barry W. Rovner, MD
Professor, Departments of Neurology, Psychiatry, and Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Jefferson Hospital for Neuroscience
Philadelphia, Pennsylvania

Marc E. Agronin, MD
Vice President, Behavioral Health and Clinical Research
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Miami, Florida

Max Lugavere
Health and Science Journalist and Filmmaker
New York, New York

James E. Galvin, MD, MPH
Professor and Associate Dean for Clinical Research
Director, Comprehensive Center for Brain Health
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida

Disclosure of Conflicts of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Richard S. Isaacson, MD Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me

Financial Support

This activity has been supported by an independent educational grant from Biogen.

Provider Information

Provided by


Release date: December 7th, 2017
Expiration date: April 5th, 2019